These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38488495)

  • 1. Prolonged viral shedding in an immunocompromised Korean patient infected with hMPXV, sub-lineage B.1.3, with acquired drug resistant mutations during tecovirimat treatment.
    Lee M; Choi CH; Kim JW; Sim G; Lee SE; Shin H; Lee JH; Choi MM; Yi H; Chung YS
    J Med Virol; 2024 Mar; 96(3):e29536. PubMed ID: 38488495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tecovirimat Resistance in an Immunocompromised Patient With Mpox and Prolonged Viral Shedding.
    Mertes H; Rezende AM; Brosius I; Naesens R; Michiels J; deBlock T; Coppens J; Van Dijck C; Bomans P; Bottieau E; Van Esbroeck M; Ariën KK; Liesenborghs L; Vercauteren K
    Ann Intern Med; 2023 Aug; 176(8):1141-1143. PubMed ID: 37487213
    [No Abstract]   [Full Text] [Related]  

  • 3. Tecovirimat Resistance in Mpox Patients, United States, 2022-2023.
    Smith TG; Gigante CM; Wynn NT; Matheny A; Davidson W; Yang Y; Condori RE; O'Connell K; Kovar L; Williams TL; Yu YC; Petersen BW; Baird N; Lowe D; Li Y; Satheshkumar PS; Hutson CL
    Emerg Infect Dis; 2023 Dec; 29(12):2426-2432. PubMed ID: 37856204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022.
    Contag CA; Mische L; Fong I; Karan A; Vaidya A; McCormick DW; Bower W; Hacker JK; Johnson K; SanJuan P; Crebbin L; Temmins C; Sahni H; Bogler Y; Cooper JD; Narasimhan S
    Emerg Infect Dis; 2023 Dec; 29(12):2520-2523. PubMed ID: 37856215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance of Complicated Mpox Cases Unresponsive to Oral Tecovirimat in Los Angeles County, 2022.
    Karan A; Shah N; Garrigues JM; Alarcόn J; Hemarajata P; Finn LE; Poortinga K; Danza P; Kulkarni S; Kim M; Terashita D; Green NM; Balter S
    J Infect Dis; 2024 Mar; 229(Supplement_2):S249-S254. PubMed ID: 37995310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: atypical presentation of mpox with massive hematochezia and prolonged viral shedding despite tecovirimat treatment.
    Shin SU; Jung Y; Kim SE; Kim DM
    BMC Infect Dis; 2024 Feb; 24(1):183. PubMed ID: 38342913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tecovirimat on healing time and viral clearance by emulation of a target trial in patients hospitalized for mpox.
    Mazzotta V; Cozzi-Lepri A; Lanini S; Mondi A; Carletti F; Tavelli A; Gagliardini R; Vita S; Pinnetti C; Aguglia C; Colavita F; Faccendini P; Matusali G; Faraglia F; Beccacece A; Paulicelli J; Girardi E; Nicastri E; Vaia F; Maggi F; Antinori A
    J Med Virol; 2023 Jun; 95(6):e28868. PubMed ID: 37306318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus.
    DeLaurentis CE; Kiser J; Zucker J
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0122622. PubMed ID: 36374026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and viral dynamics of tecovirimat in patients with MPOX: A multicenter open-label, double-arm trial in Japan.
    Akiyama Y; Morioka S; Tsuzuki S; Yoshikawa T; Yamato M; Nakamura H; Shimojima M; Takakusaki M; Saito S; Takahashi K; Sanada M; Komatsubara M; Takebuchi K; Yamaguchi E; Suzuki T; Shimokawa K; Kurosu T; Kawahara M; Oishi K; Ebihara H; Ohmagari N
    J Infect Chemother; 2024 Jun; 30(6):488-493. PubMed ID: 38042298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous tecovirimat treatment of oral monkeypox lesions in a patient with HIV-1.
    Chen WH; Axell-House DB
    J Med Virol; 2023 Sep; 95(9):e29078. PubMed ID: 37665172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection.
    Nguyen BT; Marc A; Suñer C; Marks M; Ubals M; Hernández-Rodríguez Á; Melendez MÁ; ; Hruby DE; Russo AT; Mentré F; Mitjà O; Grosenbach DW; Guedj J
    PLoS Biol; 2023 Dec; 21(12):e3002249. PubMed ID: 38127878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trifluridine for treatment of mpox infection in drug combinations in ophthalmic cell models.
    Cinatl J; Bechtel M; Reus P; Ott M; Rothweiler F; Michaelis M; Ciesek S; Bojkova D
    J Med Virol; 2024 Jan; 96(1):e29354. PubMed ID: 38180134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential.
    Russo AT; Grosenbach DW; Honeychurch KM; Long PG; Hruby DE
    Expert Rev Anti Infect Ther; 2023 Mar; 21(3):235-242. PubMed ID: 36728515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanded Access Programme for the use of tecovirimat for the treatment of monkeypox infection: A study protocol for an Expanded Access Programme.
    Bourner J; Redji Mbrenga FD; Malaka CN; Dunning J; Rojek A; Fandema E; Horby P; Boum Y; Nakouné E; Olliaro P
    PLoS One; 2024; 19(5):e0278957. PubMed ID: 38722986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical considerations on monkeypox antiviral medications: An overview.
    Pourkarim F; Entezari-Maleki T
    Pharmacol Res Perspect; 2024 Feb; 12(1):e01164. PubMed ID: 38149674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mpox in the New York metropolitan area, Summer 2022.
    Gnanaprakasam R; Keller M; Glassman R; El-Khoury MY; Chen DS; Feola N; Feldman J; Chaturvedi V
    J Med Virol; 2023 Apr; 95(4):e28699. PubMed ID: 36951318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of association between persistent skin lesion and virological replication in severe disseminated monkeypox infection in solid organ transplant recipient.
    Rousseau A; Ferrier A; Stabler S; Vuotto F; Massip E; Ouafi M; Cartier N; Ferraris O; Alidjinou EK; Faure E
    Infect Dis Now; 2023 Sep; 53(6):104749. PubMed ID: 37394180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tecovirimat for the treatment of severe Mpox in Germany.
    Hermanussen L; Brehm TT; Wolf T; Boesecke C; Schlabe S; Borgans F; Monin MB; Jensen BO; Windhaber S; Scholten S; Jordan S; Lütgehetmann M; Wiesch JSZ; Addo MM; Mikolajewska A; Niebank M; Schmiedel S
    Infection; 2023 Oct; 51(5):1563-1568. PubMed ID: 37273167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility of eighteen clinical isolates of human monkeypox virus to tecovirimat.
    Nunes DDS; Higa LM; Oliveira RL; da Costa LC; Bomfim LM; Gonçalves CCA; Mariani D; Hruby DE; Voloch CM; Castiñeiras TMPP; Tanuri A; Damaso CR
    Mem Inst Oswaldo Cruz; 2023; 118():e230056. PubMed ID: 37436275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge.
    Russo AT; Berhanu A; Bigger CB; Prigge J; Silvera PM; Grosenbach DW; Hruby D
    Vaccine; 2020 Jan; 38(3):644-654. PubMed ID: 31677948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.